Abstract
Nasal polyposis is frequently associated with chronic rhinosinusitis, high symptom burden, and poor quality of life. Options for treatment-resistant disease include aspirin desensitization, recurring systemic corticosteroid use, and sinus surgery.1 Dupilumab is a human monoclonal antibody that blocks signaling of interleukin 4 and interleukin 13. These cytokines drive allergic diseases, such as atopic dermatitis, asthma, and nasal polyposis, for which dupilumab is an approved therapy.2 In this retrospective cohort study, we aimed to evaluate real-world efficacy and safety of dupilumab in the treatment of nasal polyposis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
